The presence of AF which corresponded with subjective symptoms was confirmed on 12-lead or ambulatory 24-h ECG recording in all patients, and the clinical course had been observed for >12 months for maintaining SR.
In all patients, we performed noninvasive tests such as chest X-ray examination, ECG recording, exercise ECG testing, and echocardiography to clarify underlying heart disease before the initiation of antiarrhythmic therapy. When it was considered necessary by the treating physician, ambulatory 24-h ECG recording was repeated and cardiac catheterization was also carried out. If there were abnormal findings with regard to pulmonary disease, then pulmonary function tests and chest computed tomography (CT) scanning were performed. In this study, the plasma atrial natriuretic polypeptide (ANP) level at SR was measured in blood taken from a vein in the upper extremity while supine at rest.
Onset of AF in each group was described as follows based on symptom onset: (1) diurnal type: AF occurring between 07.00 h and 17.00 h; (2) nocturnal type: AF occurring between 17.00 h and 07.00 h the next morning; and (3) mixed type: AF occurring within both time intervals. Patients for whom the development of AF was observed on the ECG recording in addition to ambulatory 24-h ECG and for whom AF had already been identified at consultation were assigned to one of the groups. 6 All episodes in patients with AF were confirmed by the ECG recording or ambulatory 24-h ECG. For patients who already had a documented episode of AF on ECG recording during hospital visit, we defined the time of occurrence as the initiation of the same symptoms with which AF had occurred.
Patients with congestive heart failure, serious bradycardia <40 beats/min, severe intraventricular conduction disturbance, liver or renal dysfunction with abnormal laboratory test values, LV ejection fraction (LVEF) <40% determined by echocardiography, concomitantly receiving digitalis, -or calcium-channel blocker or other serious complications were excluded.
Protocol of Cardioversion
Pharmacological or electrical cardioversion under anesthesia using intravenous thiopental (2-5 mg/kg) was immediately performed for patients in whom duration of AF was <48 h. 7 For patients in whom the duration of AF was ≥48 h, pharmacological or electrical cardioversion was performed with additional intravenous administration of heparin (100 IU/kg) following confirmation of the absence of blood clots or spontaneous echo contrast in the left atrium on transesophageal echocardiography. 8 Anticoagulant treatment using warfarin was then initiated immediately after cardioversion and therapy was continued for ≥4 weeks for cases in which AF occurred before the American Heart Association (AHA) guidelines 7 were recommended. In cases of AF occurring after the recommendations of the AHA guideline, anticoagulant treatment using warfarin was administered for 3 weeks and then electrical cardioversion was performed. Warfarin was again administered for 4 weeks after obtaining cardioversion. The dose of warfarin treatment was set so as to obtain international normalized ratio between 1.6 and 2.6.
Protocol of Antiarrhythmic Agent Therapy
Patients with PAF that had been confirmed on ECG and in whom the ECG findings were clearly consistent with the subjective symptoms were registered in this study. After SR was restored by spontaneous arrest or cardioversion, an anti-arrhythmic agent, either Pil (150 mg/day) or Cib (300 mg/day), was randomly selected using the envelope method. The selected agent was regarded as the first-line agent and oral administration was begun. If recurrence of AF occurred on ECG during follow-up, another agent (the second-line agent) was orally administered from the day when spontaneous arrest was observed on follow-up monitoring. Conversely, if spontaneous arrest did not occur, another agent was orally administered as the second-line agent from the same day following performance of electrical cardioversion. The development of recurrence was determined through subjective symptoms in addition to ECG findings at 2 weeks after initial administration of the anti-arrhythmic agent or 2 weeks after switching to the second-line agent. In all patients ambulatory 24-h ECG was performed as necessary at 2 or 4 weeks after starting oral administration of the first-line or second-line agent at the time of re-consultation and was repeated at a 3-month interval or when it was considered to be necessary by the physician.
The recurrence of AF was defined as the initial episode of AF on ECG recording after the administration of the firstline or second-line agent. If recurrence of AF was observed after the administration of the second-line agent, another class I antiarrhythmic agent that had not been used before or amiodarone was administered at the discretion of the treating physician. Verbal or written informed consent regarding the therapeutic strategy in this study was given by all patients
Definitions and Statistical Analysis
PAF was defined as AF terminating spontaneously within 7 days of onset. Duration of AF was the period from the initial episode of PAF to the time of the initiation of antiarrhythmic therapy. Hypertension was defined as a casual systolic blood pressure greater than 160 mmHg at systole or 95 mmHg at diastole. 9 Ischemic stroke was diagnosed by the typical symptoms and the development of a new low- density lesion greater than 3 mm on CT scanning of the head. 10 In the pulmonary function test, we regarded FEV1.0 ≤70% as the diagnostic criterion for chronic obstructive pulmonary disease. All data are shown as mean ± standard deviation. The clinical profiles of the patients in Groups I and II were compared by one-way ANOVA for continuous variables and by the chi-square test for categorical ones. Survival curves were estimated by the Kaplan-Meier method and compared by the log-rank test. A p-value <0.05 was considered as a significant difference.
Results
The patients were divided into 2 groups according to the duration of AF as follows: Group I consisted of 22 patients who had AF lasting <48 h, ranging from 2 to 46 h (mean, 14±11 h) and Group II consisted of 38 patients whose AF lasted for ≥48 h, ranging from 52 to 864 h (mean, 184± 235 h). For the first-line agent, 29 patients received Pil and the remaining 31 patients received Cib. (Table 1) There was no difference between the 2 groups in the age, gender, bodyweight, percentages of coronary risk factors and alcohol habits, distributions of underlying heart and pulmonary diseases, period of suffering AF, LV end-diastolic dimension or LVEF determined by echocardiography, plasma concentration of ANP at SR, or the time of occurrence. The left atrial dimension was significantly greater in Group II than in Group I (p<0.01, 37±6 mm vs 32±6 mm, respectively).
Comparison of the Clinical Profiles of Groups I and II

Actuarial Recurrence-Free Rates and Period of Maintenance of SR in Group I Patients Treated With Pil or Cib
Actuarial recurrence-free rates at 1, 3, 6, 9 and 12 months were 81.8%, 68.2%, 59.1%, 50.0% and 40.9% in patients treated with Pil, and 90.9%, 77.3%, 68.2%, 59.1% and 50.0%, respectively, in those treated with Cib. There was no significant difference between the 2 groups during the follow-up period (Fig 1A) . The mean period of maintenance of SR was 12.3±2.9 months in patients treated with Pil, and 12.9±2.5 months in those treated with Cib. There was also no significant difference between the 2 groups (Fig 1B) .
Actuarial Recurrence-Free Rates and Period of Maintenance of SR in Group II Patients Treated With Pil or Cib
Actuarial recurrence-free rates at 1, 3, 6, 9 and 12 months were 44.7%, 18.4%, 10.5%, 7.9% and 2.6% in patients treated with Pil, and 63.2%, 44.7%, 28.9%, 23.7% and 18.4%, respectively, in those treated with Cib. Actuarial recurrence free rates at 12 months were significantly higher in patients treated with Cib than in those treated with Pil (p<0.05, Fig 2A) . The mean period of maintenance of SR was 1.6±0.5 months in patients treated with Pil, and 5.9±1.7 months in those treated with Cib. The mean period of maintenance of SR was significantly higher in patients treated with Cib than in those treated with Pil (p<0.01, Fig 2B) .
Results of Pharmacological/Electrical Cardioversion in Patients With PAF
Pharmacological cardioversion was performed first for 22 cases in Group I and 8 cases in Group II (30/60 subjects), with a total success rate of 30% (8 of 22 cases in Group I (36%), 1 of 8 cases in Group II (13%)). No significant differences were noted between the groups (p=NS). Electrical cardioversion was performed for 14 cases in Group I and 37 cases in Group II in whom AF recurred during the administration of the first-line agent and had to be changed, a total of 51 cases, and successful cardioversion was achieved in all cases. In addition, conversion to permanent AF occurred in 10 of 60 cases (15%) despite aggressive antiarrhythmic drug therapy.
Discussion
The up-or down-regulation of various ion channels occurs gradually in atrial muscle after prolonged rapid atrial pacing in experimental animal models. It is considered that these changes in atrial muscle are reversible if rapid atrial pacing only lasts several weeks or several months. If the atrial tachycardia lasts for several years or more, however, the changes become irreversible because myocardial fibrosis and degeneration occur in the atrial muscle. 11 In experimental reports from animal models in which tachycardia lasted several hours to several months, there was down-regulation of the L-type calcium current (IcaL) 12,13 associated with excessive intracellular calcium loading, and down-regulation in the ultrarapid delayed rectifier potassium current (Ikur), 14 transient outward potassium current (Ito), 13 sodium current (INa) 15 and slow-type delayed rectifier potassium current (Iks) 16 as an up-regulation of ion channels. In human atrial muscle that has been converted to permanent AF, down-regulation of ion channels such as the L-type calcium current (IcaL) 17 and transient outward potassium current (Ito), 18 and up-regulation of the inward potassium current (Ikl) and acetylcholine-activated potassium current (IKach) 17 have been reported, whereas neither the ultrarapid delayed rectifier potassium current (Ikur) 18 nor rapid delayed rectifier potassium current (Ikr) 19 showed any changes. Those changes in the ion channels result in a shortened effective refractory period of atrial muscle and shortened excitable wave lengths according to the reduction of conduction velocity. Eventually, the arrhythmogenic substrate in which AF can be easily induced and prolonged is developed. 19 In the present study, we divided patients with PAF into 2 groups according to the duration of AF: Group I consisted of patients in whom AF lasted for <48 h and Group II consisted of those in whom AF lasted for ≥48 h. The AHA guideline recommends that patients in whom AF lasts ≥48 h should be converted to SR by pharmacological and/or electrical cardioversion after adequate anticoagulant therapy, for 3 weeks before cardioversion and for 4 weeks afterward. 7 All of the present patients in whom AF lasted ≥48 h underwent anticoagulant therapy before cardioversion, although eventually the strategy for restoring SR was determined by whether the duration of AF was ≥48 h or not. Accordingly, the atrial muscle in patients with AF lasting ≥48 h was more likely to have been influenced by up-or down-regulation of various ion channels caused by prolong tachycardia for the following reasons: cardioversion was performed after AF had lasted 10 or more days from the episode of PAF, and patients in the present study with spontaneous AF tend to have inherently arrhythmogenic substrates.
The present study showed no significant differences in the recurrence free rate between the Pil and Cib groups of patients in whom AF lasted <48 h, whereas the recurrence free rate was significantly higher in the Cib group than in the Pil group of patients in whom AF lasted ≥48 h at 12 months. Generally, Pil is considered to have a pure sodiumchannel-blocking action on single cardiac muscle cells. 20 If down-regulation of the sodium current (INa) has been caused by the development of atrial remodeling of patients in whom AF lasted for ≥48 h, the preferred pharmacological action in relation to the ion channel may not occur in those patients. On the other hand, Cib is considered to have a multichannel blocking action, which blocks potassium and calcium channels in addition to the sodium channel. 20 In relation to its potassium channel-blocking action, there have been reports that Cib blocks the rapid (Ikr) as well as the slow (Iks) delayed rectifier potassium currents, inward potassium current (Ikl) and acetylcholine-activated potassium current (IKach). 21, 22 Because those ion channels were up-regulated or unchanged by the development of atrial remodeling following prolonged tachycardia, the preferred pharmacological action is expected. In fact, the present study showed that the recurrence-free rate in the Cib group was significantly higher than in the Pil group of patients in whom AF lasted for ≥48 h.
During a follow-up period of 12 months, we found that the recurrence-free rate of patients treated with Pil and Cib in whom AF lasted <48 h was approximately 40-50%, which is consistent with that reported previously. 23, 24 In contrast, the recurrence-free rate of those in whom AF lasted for ≥48 h was 3-18%, which was lower than in the previous reports. Some reasons for this result are: those patients finally had repeated AF recurrence despite the use of approximately 4 different antiarrhythmic agents on average after this trial; most of those patients had been suffering from PAF for approximately 2 years from the initial episode; 25 70% of those patients consisted of the mixed type according to the time of the occurrence and the AF was refractory to antiarrhythmic agent therapy; 6 less than 20% of those patients were receiving concomitant angiotensin-converting enzyme inhibitor, 26 which is considered to enhance the prevention of AF recurrence.
Study Limitations
The recurrence-free rate of patients treated with Pil and Cib was not compared with that of a placebo group, so the possibility of maintenance of SR even without any antiarrhythmic agents cannot be excluded. Some large clinical trials have demonstrated that the recurrence-free rate of patients treated with placebo was 7% 27 at 1 month, and 8-24% 28,29 at 2 and 3 months. In Japan, the SMART study (Sinus rhythm Maintenance in Atrial Fibrillation Randomized Trial) showed that the recurrence-free rate in a placebo group was 21% at 6 months. 30 Thus, there are differences in the recurrence-free rate in patients treated with placebo among the several clinical reports in which study patients with various clinical profiles were evaluated. All of the present patients, however, were symptomatic and needed antiarrhythmic agent therapy. A placebo effect was unlikely to have affected our results because the follow-up period was longer (at 12 months) than in the previous reports and the study patients consisted of those with recurrent and symptomatic PAF.
Page et al, reported that in patients with PAF, sustained asymptomatic AF occurs far more frequently than symptomatic AF. 31 In the present study, all patients were considered to have no AF recurrence based on the symptoms and ECG findings taken once or twice a month at the outpatient clinic. The possibility of the occurrence of asymptomatic AF episodes in these patients cannot be excluded completely. According to another study in patients with symptomatic AF using Cardiophone (a portable ECG system), however, 30-70% of symptoms such as palpitation turned out to be sinus tachycardia or atrial extrasystole without PAF. 32 From those results, the duration of tachycardia might be subjectively evaluated as in previous reports 31, 32 if the duration of tachycardia in patients for whom AF had been observed at initial consultation was defined as between the onset of similar AF symptoms and the initial consultation. There is currently a methodological limitation in evaluating the initial episode of AF recurrence accurately by means of the symptoms and ECG findings.
Conclusion
Prolonged tachycardia (≥48 h) in patients with PAF seems to cause electrical remodeling. Cib, a multichannel blocker, appears to be more effective in preventing the recurrence of PAF in electrically remodeled atria than Pil, a pure sodium-channel blocker. In addition, early cardioversion increases the subsequent long-term preventive effect of antiarrhythmic agent in patients with PAF.
